Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski explain the importance of transparency and collaboration when encountering manufacturing speed bumps.

Profluent Bio’s Hilary Eaton is passionate about developing technology that tackles rare diseases on the genetic level, an issue that personally affects her and her family.

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

In this executive virtual roundtable (EVR) component, Usama Malik, CEO of Fore Biotherapeutics, discusses the challenges faced as a startup CEO trying to fill multiple positions during a red-hot ...

Francois is chairman of the board at Acceleron Pharma. He is the former CEO of NPS Pharmaceuticals and serves on several other corporate and philanthropy boards.

Woody Bryan, Ph.D. has founded several biotech companies during his career, and he explains how his journey from scientist to business development prepared him for the C-suite.

Biopharma guru Allan Shaw speculates on the risks and benefits that the incoming Trump administration could bring to the industry.